New Study Shows COVID-19 Immunity Can Last at Least Eight Months After Infection
11 Jan 2021
AntibodyVaccine
Evidence continues to build for long-lasting immunity to COVID-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms. The latest peer-reviewed study, published last week in Science, echoes several non-peer-reviewed studies published last year.
In the study, researchers from La Jolla Institute for Immunology and elsewhere tested antibodies, memory B cells and memory T cells specific to SARS-CoV-2 or its Spike protein, collected from 188 patients between 5-8 months following infection and the onset of COVID-19 symptoms. Levels of Spike-specific immunoglobulin G (IgG) antibodies remained stable over 6-8 months, with 90% of subjects testing positive for the IgG.
Longitudinal tracking of some samples showed levels of spike-specific SARS-CoV-2 memory B cells increased over the course of 6 months. Memory CD4+ and CD8+ T cells were also detected over 6 months after onset of symptoms in 92% and 50% of patients, respectively.
The researchers also showed that Spike- and receptor binding domain-specific antibodies and memory B cells were higher 4 months following symptoms onset in more severe Covid-19 cases requiring hospitalizations, compared with less severe cases. Although data is not conclusive, previous studies in animals hint that increased antibody levels may provide sterilizing immunity to Covid-19, and the presence of memory B and T cells may limit infections that cannot be sterilized to low-severity or asymptomatic illness.
The findings are consistent with previous research. In a November pre-print, which has not yet been peer reviewed, British researchers showed robust T cell immunity six months after infection, with levels correlating to the severity of initial infection in 100 patients. A second pre-print published days later, led by The Rockefeller University researchers, showed the presence of antibodies and memory B cells six months after infection.
Work is ongoing to connect the dots between immune memory dynamics and the ability to prevent severe reinfection. A paper published in the New England Journal of Medicine in December, led by University of Oxford researchers, followed health care workers and found that over six months, only 2 out of 1,265 people that originally tested positive for COVID-19 later showed reinfection – and both patients were asymptomatic.
The immune memory data also has implications for the longevity of vaccine protection. Although long-term data is not available, Moderna CEO Stephane Bancel said on January 7 that he expects protection from the company’s COVID-19 vaccineCOVID-19 vaccine to last years.
The La Jolla Institute for Immunology study first appeared as a preprint in November, prior to completion of peer review.
Most Read Today
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.